Inhalative administration of fibrinogen IIb/IIIa receptor antagonists for prompt acute therapy in the event of thrombus formatio
The effect of the intravenously administered fibrinogen IIb/IIIa receptor antagonist Tirofiban as a thrombocyte aggregation inhibitor is known and well investigated. Now, for the first time, the dispersal of Tirofiban in the form of an aerosol has been achieved, which allows application of the produced aerosol via inhalation. This has the advantage that the active ingredients are reabsorbed very quickly after deposition and rapidly reach a therapeutically active drug level in the blood, which leads to life-saving thrombocyte aggregation inhibition. With this the possibility for acute and immediate treatment of diseases which are caused by or in conjunction with thrombus formation is finally available.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Bringing bio-inspired robots to life
Nebraska researcher Eric Markvicka gets NSF CAREER Award to pursue manufacture of novel materials for soft robotics and stretchable electronics. Engineers are increasingly eager to develop robots that mimic the…
Bella moths use poison to attract mates
Scientists are closer to finding out how. Pyrrolizidine alkaloids are as bitter and toxic as they are hard to pronounce. They’re produced by several different types of plants and are…
AI tool creates ‘synthetic’ images of cells
…for enhanced microscopy analysis. Observing individual cells through microscopes can reveal a range of important cell biological phenomena that frequently play a role in human diseases, but the process of…
